


- ZnCl<sub>2</sub>). Typical yields obtained were 1 mg of >90% pure T7EX556 per liter of starting culture.
- F. Payvar *et al.*, *Cell* **35**, 381 (1983).
  - W. C. Soeller *et al.*, *Genes Dev.* **2**, 68 (1988).
  - U. Heberlein and R. Tjian, *Nature* **331**, 410 (1988).
  - J. LaBaer, thesis, University of California, San Francisco (1989).
  - R. Schüle *et al.*, *Science* **242**, 1418 (1988).
  - DNA fragments without GREs were inserted into the Xba I site (see Fig. 2) of -33 GRE<sub>6</sub>, displacing the GRE cassette to -262, -366, and -1069 bp from the start of transcription. Weak receptor-mediated activation was detected when GREs were situated at -262, but no effect was observed from the more distal sites.
  - A. Sergeant, D. Bohman, H. Zentgraf, H. Weihler, W. Keller, *J. Mol. Biol.* **180**, 577 (1984); P. Sassone-Corsi, A. Wilderman, P. Chambon, *Nature* **313**, 458 (1985); H. R. Scholer and P. Gruss, *EMBO J.* **4**, 3005 (1985); Y.-S. Lin, M. F. Carey, M. Ptashne, M. R. Green, *Cell* **54**, 659 (1988).
  - L. P. Freedman, unpublished.

- A. Fire, U. Samuels, P. A. Sharp, *J. Biol. Chem.* **259**, 2509 (1984); D. K. Hawley and R. G. Roeder, *ibid.* **262**, 3452 (1987).
- B. Corthésy *et al.*, *Science* **239**, 1137 (1988).
- S. K. Yoshinaga and L. P. Freedman, unpublished.
- K. A. Jones *et al.*, *Cell* **42**, 559 (1985).
- C. Scheidereit and M. Beato, *Proc. Natl. Acad. Sci. U.S.A.* **81**, 3029 (1984).
- H. M. Jantzen *et al.*, *Cell* **49**, 29 (1987).
- We thank W. Soeller for embryo extracts and discussions; M. Biggin, B. England, D. Granner, J. LaBaer, and D. Picard for DNA reagents; S. Johnson and R. Myers for critical readings of the manuscript; and K. Mulherin and B. Maler for preparation of the text and figures, respectively. Supported by grants from the National Institutes of Health and the National Science Foundation; postdoctoral support was from the American Cancer Society, California Division (S.K.Y.), and from the Bank of America-Giannini Foundation (L.P.F.).

18 April 1989; accepted 2 June 1989

**Fig. 1.** Molecular weight of the cell surface antigen APO-1: immunoprecipitation of biosynthetically labeled APO-1 from the surface of SKW6.4 cells with either isotype-matched control MAb (left lane) or anti-APO-1 (right lane). The numbers on the left margin indicate the positions of the size markers. Cells ( $3 \times 10^6$ ) were labeled with 60  $\mu$ Ci of <sup>75</sup>Se-labeled methionine (Amersham, Braunschweig, FRG) in 6 ml of methionine-free culture medium (Biochrom, Berlin) for 48 hours. After washing, the cells were incubated in either control MAb or anti-APO-1 (1  $\mu$ g/ml) at 4°C for 45 min. The cells were washed and resuspended in lysis buffer (tris-buffered saline, pH 7.3, 1% Nonidet P-40, 1 mM phenylmethylsulfonyl fluoride, 0.1% aprotinin) at room temperature for 30 min. The lysates were centrifuged and supernatants were incubated with protein A-Sepharose beads (Pharmacia, Uppsala, Sweden) at 4°C for 1 hour. The immune complexes were washed four times with buffer (tris-buffered saline, pH 7.3, 0.25% Nonidet P-40) and resuspended in SDS-PAGE sample buffer containing 5% SDS and 5% 2-mercaptoethanol. The samples were heated to 95°C, centrifuged, and counts per minute of the supernatants were determined in a  $\gamma$ -counter. A total of 15,000 cpm were loaded in each lane and analyzed by a 10% SDS-PAGE (18). The gel was dried and subjected to autoradiography.



polyacrylamide gel electrophoresis (SDS-PAGE) as a main band of 52 kD (Fig. 1). Apart from actin (43 kD), which was non-specifically precipitated with IgG3, anti-APO-1 specifically immunoprecipitated a minor band of 25 kD. This 25-kD protein might either represent a degradation product or be noncovalently associated with the 52-kD protein.

There are two major modes of death in nucleated eukaryotic cells. Necrosis as a result, for example, of complement attack is characterized by swelling of the cells and rupture of the plasma membrane caused by an increase in permeability. Cells that undergo apoptosis, however, show a different biochemical and morphological pattern (2). This pattern corresponds to the one induced by anti-APO-1: condensation of the cytoplasm, membrane blebbing (Fig. 2a), and endonuclease-induced DNA fragmentation (5) into multimers of approximately 180 bp

B. C. Trauth, C. Klas, A. M. J. Peters, W. Falk, P. H. Kramer, Institute for Immunology and Genetics, German Cancer Research Center, Heidelberg, Federal Republic of Germany.  
 S. Matzku, Institute for Radiology and Pathophysiology, German Cancer Research Center, Heidelberg, Federal Republic of Germany.  
 P. Möller, Institute for Pathology of the University of Heidelberg, Federal Republic of Germany.  
 K.-M. Debatin, Oncology/Immunology Section, University Children's Hospital, Heidelberg, Federal Republic of Germany.

\*To whom correspondence should be addressed:

## Monoclonal Antibody-Mediated Tumor Regression by Induction of Apoptosis

BERNHARD C. TRAUTH, CHRISTIANE KLAS, ANKE M. J. PETERS, SIEGFRIED MATZKU, PETER MÖLLER, WERNER FALK, KLAUS-MICHAEL DEBATIN, PETER H. KRAMMER\*

To characterize cell surface molecules involved in control of growth of malignant lymphocytes, monoclonal antibodies were raised against the human B lymphoblast cell line SKW6.4. One monoclonal antibody, anti-APO-1, reacted with a 52-kilodalton antigen (APO-1) on a set of activated human lymphocytes, on malignant human lymphocyte lines, and on some patient-derived leukemic cells. Nanogram quantities of anti-APO-1 completely blocked proliferation of cells bearing APO-1 in vitro in a manner characteristic of a process called programmed cell death or apoptosis. Cell death was preceded by changes in cell morphology and fragmentation of DNA. This process was distinct from antibody- and complement-dependent cell lysis and was mediated by the antibody alone. A single intravenous injection of anti-APO-1 into *nu/nu* mice carrying a xenotransplant of a human B cell tumor induced regression of this tumor within a few days. Histological thin sections of the regressing tumor showed that anti-APO-1 was able to induce apoptosis in vivo. Thus, induction of apoptosis as a consequence of a signal mediated through cell surface molecules like APO-1 may be a useful therapeutic approach in treatment of malignancy.

CELL SURFACE MOLECULES ARE CRUCIAL in lymphocyte growth control. Such molecules may function as receptors for growth-stimulating cytokines or be associated with receptors and transmit signals essential for growth regulation. Receptor blockade or removal of the stimulating cytokines can lead to decreased lymphocyte growth. Withdrawal of interleukins slow human lymphocyte growth and finally leads to a characteristic form of cell death called "programmed cell death" or apoptosis (1). Apoptosis is the most common form of eukaryotic cell death and occurs in embryogenesis, metamorphosis, tissue atrophy, and tumor regression (2). It is also induced by cytotoxic T lymphocytes and natural killer and killer cells; by cytokines like tumor necrosis factor (TNF) and lymphotoxin (LT); and by glucocorticoids (1, 2). The

most characteristic signs of apoptosis are segmentation of the nucleus, condensation of the cytoplasm, membrane blebbing, and DNA fragmentation into multimers of about 180 base pairs (called a "DNA ladder") (1, 2). To analyze mechanisms of lymphocyte growth control and to interfere with the replication of lymphoid tumor cells we raised monoclonal antibodies (MAbs) against cell surface molecules involved in these processes.


We found one MAb (anti-APO-1) that blocks growth and induces apoptosis of SKW6.4 cells (3). Anti-APO-1 (IgG3,  $\kappa$ ,  $K_D = 1.9 \times 10^{-10}$ ) bound to approximately  $4 \times 10^4$  sites on the surface of SKW6.4 cells (4). It specifically immunoprecipitated an endogenously synthesized protein antigen (APO-1) from SKW6.4 cells which, under reducing conditions, was observed on SDS-

(Fig. 2b). Affinity-purified anti-APO-1 induced growth retardation and cell death (Fig. 2c), which was not observed with either an isotype-matched, control MAb (FII20) [anti-MHC (major histocompatibility complex) class I antigens] or the non-binding MAb FII23. Abrogation of [<sup>3</sup>H]thymidine incorporation along with increased trypan blue uptake into dead cells were observed, and growth of 10<sup>4</sup> SKW6.4 cells in 200- $\mu$ l cultures was blocked by more than 95% by an anti-APO-1 concentration of only 10 ng/ml (Fig. 2c). The specificity of cell death induced by anti-APO-1 becomes evident from the fact that the following additional control MAbs were inactive for induction of apoptosis: 18 nonbinding and 9 binding MAbs of the IgG3 isotype (tested by immunofluorescence on SKW6.4 cells) and a panel of MAbs directed against known antigens on the cell surface of SKW6.4 cells including CD19, CD20, CD22, MHC class




II, IgM (immunoglobulin M), and the SKW6.4 idiotype (6).

Cell death induced by anti-APO-1 was complement-independent and occurred under serum-free culture conditions or in culture medium plus serum inactivated at 56°C for 30 min. It differed from death mediated by complement-dependent lysis by: (i) morphology and formation of a DNA ladder (Fig. 2, a and b), (ii) exogenous Ca<sup>2+</sup> independence (7), and (iii) delayed trypan blue uptake and delayed <sup>51</sup>Cr release from radiolabeled target cells (8). These experiments indicate that cell death induced by anti-APO-1 is fundamentally different from antibody- and complement-dependent cell lysis.

To assess the specificity of anti-APO-1, a restricted panel of tumor cell lines was screened for expression of APO-1 and susceptibility to growth inhibition and apoptosis. APO-1 was expressed on various human



**Fig. 2.** Induction of growth inhibition and apoptosis by anti-APO-1. **(A)** The T cell line CCRF-CEM.S2 (19) was cultured in the presence of purified MAb (1  $\mu$ g/ml) in a microtiter plate for 2 hours before photography (left panel control MAb 13B1; right panel anti-APO-1). **(B)** CCRF-CEM.S2 cells (10<sup>6</sup> per milliliter) were incubated with MAb (1  $\mu$ g/ml) in culture medium at 37°C. At various times, aliquots of 10<sup>6</sup> cells were removed and DNA was prepared. M, marker; I, control MAb 13B1 for 2 hours; lanes 3 to 7, anti-APO-1 for the times indicated. **(C)** SKW6.4 cells were either incubated with the isotype-matched control MAb FII20 ( $\square$ ), FII23 (nonbinding MAb) ( $\circ$ ), or anti-APO-1 ( $\bullet$ ) in microcultures for 24 hours before labeling with [<sup>3</sup>H]thymidine for a further 4 hours. The data represent the mean of duplicate cultures with a variation of less than 5%. The cells were cultured in RPMI 1640 medium (Gibco, Grand Island, New York), supplemented with 2 mM L-glutamine, streptomycin (100  $\mu$ g/ml), penicillin (100 U/ml), 20 mM HEPES buffer pH 7.3, and 10% heat-inactivated fetal bovine serum (Conco Lab-Division, Wiesbaden, FRG). For microcultures, 1  $\times$  10<sup>4</sup> cells per well were cultured in duplicates in flat-bottom 96-well microtiter plates (Tecnomara, Fernwald, FRG) (200  $\mu$ l final volume per well). After 24 hours, the cells were labeled with 0.5  $\mu$ Ci of [<sup>3</sup>H]thymidine (Amersham, Braunschweig, FRG) for 4 hours. Before harvesting, the microcultures were examined by microscopic inspection. DNA fragmentation 1  $\times$  10<sup>6</sup> cells were washed with cold phosphate-buffered saline and disrupted with NTE buffer, pH 8 (100 mM NaCl, 10 mM Tris, 1 mM EDTA) containing 1% SDS and proteinase K (0.2 mg/ml). After incubation for 24 hours at 37°C, samples were extracted twice with phenol plus chloroform (1:1, v/v) and precipitated by ethanol. The DNA was dissolved in 38  $\mu$ l of NTE buffer and digested with ribonuclease (1 mg/ml) for 30 min at 37°C. To each sample 10  $\mu$ l of loading buffer containing 15% Ficoll 400 (Pharmacia, Uppsala, Sweden), 0.5% SDS, 50 mM EDTA, 0.05% bromophenol blue, 0.05% xylene cyanol in TBE buffer (2 mM EDTA, 89 mM boric acid, 89 mM Tris, pH 8.4) were added. The mixture was loaded onto a 1% agarose gel and stained after electrophoresis with ethidium bromide (0.5  $\mu$ g/ml). The size marker was Hind III + Eco RI-digested  $\lambda$  DNA.




**Fig. 3.** Anti-APO-1-induced regression of the EBV-negative Burkitt-like lymphoma BJAB in *nu/nu* mice. BJAB cells ( $4 \times 10^7$ ) were injected subcutaneously into the left flank of *nu/nu* mice. After 5 weeks (day 0) the mice were injected with 500  $\mu$ g of MAb into the tail vein. Control MAb FII20 ( $\square$ ); FII23 ( $\circ$ ); I3B1 ( $\Delta$ ); and anti-APO-1 ( $\bullet$ ). Fourteen days later the size of the tumors was measured at the base of the tumor; the tumors from individual mice are represented by dots.

lymphoid B and T cell lines and was not found on a gibbon or mouse T cell line or a human monocytic cell line (Table 1). Anti-APO-1 blocked proliferation of the APO-1-positive cell lines listed in Table 1 via induction of apoptosis, and formation of a DNA ladder was observed in each case (9). Expression of APO-1 was not restricted to cell lines in vitro but could be found on leukemic cells freshly isolated from patients (Table 1). Since APO-1 was not found on all leukemic cells it may be possible that anti-APO-1 defines a subpopulation of leukemias.

We also screened human B and T cells for expression of APO-1. We did not detect APO-1 on resting B cells. However, APO-1 was expressed on activated B cells (Table 1) and IgM secretion was reduced approximately fourfold by 3 days of treatment with anti-APO-1 (10). Peripheral resting T cells did not express APO-1. Activated T cells, however, expressed APO-1 and anti-APO-1-induced apoptosis and growth inhibition of these cells (Table 1). Thus, our data suggest that APO-1 is a species-specific antigen expressed on activated or malignant lymphocytes.

The striking effect of anti-APO-1 in vitro prompted us to test its effect on tumor growth in vivo. Although the Epstein-Barr virus (EBV)-negative, Burkitt-like lymphoma BJAB was the least sensitive to anti-APO-1 of the B cell panel in Table 1 and expressed only approximately  $1.5 \times 10^4$  APO-1 epitopes per cell (4), we selected BJAB for our in vivo experiments. The reason for this choice was that only BJAB grew to large tumor masses in unirradiated *nu/nu* mice. Five weeks after injection of

**Fig. 4.** Localization of anti-APO-1 in xenografts of BJAB in *nu/nu* mice and induction of apoptosis of the tumor. (A) Upper row: uptake of <sup>125</sup>I-labeled MAb anti-APO-1 (50 μg, 50 μCi per mouse) in the tumor at 12 hours (1), 48 hours (2), and 96 hours (3) after intravenous injection of the MAb. Lower row: uptake of <sup>125</sup>I-labeled MAb anti-APO-1 (500 μg, as used for therapy; 50 μCi per mouse) (4) and FII20 (control MAb, binding to BJAB; 50 μg, 50 μCi per mouse) (5) and <sup>125</sup>I-labeled FII23 (control MAb, nonbinding to BJAB; 50 μg, 50 μCi per mouse) (6) in 48 hours, respectively. (B) Ten days after intravenous injection of 500 μg of MAb per mouse the remaining tumor tissue was removed and fixed with formalin. Paraffin sections of the tumor were stained with haematoxylin/eosin. Left panel, tumor after treatment with control MAb FII20; right panel, tumor after treatment with anti-APO-1. Arrows



indicate host vessels. Final magnification, × 92. MAbs were radioiodinated according to the IODO-Gen method (4). Labeled MAbs were injected into the tail vein and animals were killed by ether anesthesia at the predetermined time points. The tumors were excised and embedded in methylcellulose and 20-μm cryotome sections were prepared. Lyophilized sections were placed on a Kodak X-omat AR film for autoradiography.

BJAB cells the *nu/nu* mice carried tumors with a diameter of approximately 1.0 to 2.5 cm (Fig. 3). These mice were injected intravenously with purified anti-APO-1 (500 μg per mouse) or the same quantities of various isotype-matched control antibodies (FII20, anti-MHC class I antigens, recognizing  $5.8 \times 10^5$  sites per cell; or one of the two nonbinding MAbs FII23 and I3B1). As a control we also injected anti-APO-1 (500 μg per mouse) into three *nu/nu* mice carrying the APO-1-negative B cell tumor OCI.LY1 with tumor diameters of 1.5, 1.8, and 3.4 cm, respectively (11) (see also Table 1). Two days after anti-APO-1 injection, a whitish discoloration of the BJAB tumors was observed that was followed by rapid tumor regression. Macroscopic tumor regression was seen in 10 of 11 treated mice within less than 14 days. The control antibodies had no effect (Fig. 3). In addition, no tumor regression was observed in the mice carrying OCI.LY1, as expected.

To demonstrate proper localization and enrichment of the injected antibodies, labeled MAbs were visualized by autoradiography of sections of the BJAB tumor tissue (Fig. 4a). These autoradiographs showed a pronounced binding of anti-APO-1 in the periphery but only sparse accumulation in the center of the tumor. The binding control MAb FII20 showed a qualitatively similar binding pattern. There was no localization of the nonbinding control MAb FII23 above background. Furthermore, paired label experiments (12) with labeled anti-APO-1 and FII23 revealed that the specific enrichment of anti-APO-1 over FII23 in the tumor was four- and sixfold after 48 and 96 hours, respectively.

The main purpose of our experiments was to assess whether anti-APO-1 can also act in vivo. Therefore, the tumor-bearing mice only received one intravenous injection of anti-APO-1 at a dose in the range used in

**Table 1.** Reactivity of anti-APO-1 with different cells.

Cells*		Cells positive for APO-1 (%)†	Relative fluorescence intensity (anti-APO-1/control)	Effects of MAbs on [ <sup>3</sup> H]thymidine uptake (10 <sup>3</sup> cpm)‡	
Type	Designation			Control	Anti-APO-1
<i>Malignant cell lines</i>					
Hu B cells	SKW6.4	98	11.1	30.0	0.02
	CESS	95	12.0	23.0	0.1
	BJAB	80	2.1	70.0	7.0
	OCI.LY1	0	1	14.5	15.8
Hu T cells	Jurkat	83	2.3	20.3	8.1
	Molt	91	2.4	35.7	0.6
	CCRF-CEM	64	1.9	16.2	0.5
Hu myeloid cells	U937	5	0.97	62.2	60.5
Gibbon T cells	MLA 144	0	0.96	34.3	35.0
Mouse T cells	EL4	0	1	44.8	45.3
<i>Leukemic cells from patients§</i>					
Pre T-ALL	B.M.	54	4.4		
T-ALL	D.A.	53	3.2		
Common ALL	W.N.	72	5.0		
<i>Normal human lymphocytes</i>					
T cells	Resting	3	1.36		
	Activated	89	7.4	22.4	0.23
B cells¶	Resting	0	0.9		
	Activated	91	1.1		

\*Hu, human; ALL, acute lymphocytic leukemia. †Aliquots of 10<sup>6</sup> cells were incubated at 4°C in 100 μl of medium with control MAb (FII23 or I3B1) or anti-APO-1 for 30 min. Then the cells were washed and stained with fluorescein isothiocyanate-coupled goat anti-mouse Ig F(ab')<sub>2</sub> (70 μg/ml) and analyzed by a cytofluorograph (Ortho Diagnostic Systems, Westwood, Massachusetts). ‡Cells (10<sup>4</sup> per well) were cultured in the presence of MAb (500 ng/ml) for 24 hours and labeled with [<sup>3</sup>H]thymidine for 2 hours before harvest; the data represent the mean of duplicate cultures with a variation of less than 5%. §Bone marrow cells isolated from the patients were morphologically >95% blasts and showed the following phenotype: pre T-ALL, cytoplasmic CD3<sup>+</sup>, CD5<sup>+</sup>, CD7<sup>+</sup>, CD34<sup>+</sup>, Tdr<sup>+</sup>, CD2<sup>-</sup>, surface CD3<sup>-</sup>, CD4<sup>-</sup>, and CD8<sup>-</sup>; T-ALL CD2<sup>+</sup>, cytoplasmic CD3<sup>+</sup>, CD5<sup>+</sup>, CD7<sup>+</sup> and Tdr<sup>+</sup>, surface CD3<sup>-</sup>, CD4<sup>+</sup>, CD8<sup>-</sup>, and CD34<sup>-</sup>; common-ALL CD10<sup>+</sup>, CD19<sup>+</sup>, CD22<sup>+</sup>, CD24<sup>+</sup>, CD20<sup>-</sup>. The effect of anti-APO-1 on these leukemic cells was not tested, because they died under normal culture conditions. ||Peripheral blood mononuclear cells (PBMC) from healthy volunteers were isolated by Ficoll Paque (Pharmacia Inc., Uppsala, Sweden) density centrifugation. Adherent cells were removed by adherence to plastic culture vessels overnight. T cells were isolated from PBMC by rosetting with 2 amino-ethylisothiouonium-bromide (AET)-treated sheep red blood cells as described (20). Freshly prepared resting T cells (2 × 10<sup>6</sup> per milliliter; 96% OKT11<sup>+</sup>, 1% Tac<sup>+</sup>) were activated with phytohemagglutinin-M (50 μg/ml) and PMA (10 ng/ml) (Sigma Chemical Co., Munich, FRG). Two, 7, and 12 days later the T cells were fed with 20 to 30 U/ml of recombinant human interleukin-2 (20 to 30 U/ml). T cells (5 × 10<sup>5</sup> per milliliter) activated for 12 days (90% OKT11<sup>+</sup>; 60% Tac<sup>+</sup>) were cultured in the presence of FII23 or anti-APO-1 (1 μg/ml) in triplicates for 24 hours and then labeled with [<sup>3</sup>H]thymidine for a further 17 hours (see legend to Fig. 2). ¶Resting B cells (35.8% CD19<sup>+</sup>) were isolated by two rounds of rosetting as above, followed by separation via a Sephadex G-10 column as described (21). For activated B cells, PBMC were adjusted to 2 × 10<sup>6</sup> cells per milliliter and cultured in the presence of pokeweed mitogen at 10 μg/ml (Serva, Heidelberg, FRG) for 6 days. Dead cells and T cells were then eliminated by rosetting with AET-treated sheep red blood cells and subsequent centrifugation over Ficoll Paque. The interphase cells were used as activated B cells (84% sIgM<sup>+</sup>).

MAB therapies. In other therapy schedules, however, MAbs are injected repeatedly (13). In our experiments regrowth of the BJAB

tumor was observed in three of the ten mice in which tumor regression had been observed (Fig. 3). Regrowth was observed at

the margin of the original tumor approximately 3 months after the initial macroscopic tumor regression. One of these tumors was removed and found to express APO-1 by immunofluorescence and to be sensitive to anti-APO-1 in vitro at a MAb concentration similar to the original in vitro BJAB tumor cell line (Table 1).

To determine the histology of the regressing BJAB tumors we prepared thin sections of tumors from MAb-treated *nu/nu* mice. Ten days after intravenous injection of FII20, BJAB appeared as a solid tumor composed of densely packed large blasts with numerous mitoses, some tumor giant cells, and rare apoptotic figures (Fig. 4b, left panel). The tumor was penetrated by host vessels. In contrast, almost all remaining BJAB cells of mice treated with anti-APO-1 (Fig. 4b, right panel) showed severe cytopathic changes including nuclear pyknosis and cellular edema most pronounced in perivascular microareas. These morphological changes are characteristic of apoptosis.

Taken together, these data strongly suggest that apoptosis is induced by anti-APO-1 and is the mechanism of death and regression of BJAB tumor cells in vivo. The fact that FII20, which strongly binds to the cell surface of BJAB tumor cells, did not cause regression of BJAB also precludes the possibility that killer cells or complement that might have bound to anti-APO-1 may have been involved in the growth inhibition and tumor regression.

We showed that anti-APO-1 specifically blocked growth and triggered programmed cell death (apoptosis) of a set of activated normal lymphocytes and cells from malignant lymphocyte lines after binding to the cell surface protein antigen APO-1. Recently, it has been shown that anti-CD3 induces apoptosis of immature thymocytes in vitro (14). Therefore, it has been suggested that CD3-triggered apoptosis might be responsible for negative selection of T cells in the thymus. Since APO-1 is expressed on mature activated lymphocytes, additional experiments will be needed to determine whether the antigen might play a similar role in the downregulation of the immune response and be involved in selection and elimination of lymphocytes. It has previously been shown that LT, TNF, and killer cells with their effector molecules induce apoptotic cell death (15). As anti-APO-1 also induces apoptosis a number of possibilities might be considered for the physiological role of the APO-1 antigen. APO-1 might be a receptor for cytotoxic molecules or for autocrine growth factors. Alternatively, it could be a molecule essential for vertical or lateral growth signal transduction. Thus, anti-APO-1 might trigger receptors for lytic

molecules or block receptors for growth signals.

Apoptosis is found in all tissues and also in cells from lower organisms (16). It is conceivable, therefore, that several distinct cell surface antigens with a different tissue distribution are involved in the induction of apoptosis. Elucidation of the structure of APO-1, its possible connection to the cytoskeleton and the molecular events following anti-APO-1 binding might resolve some of these issues.

Our data might also have clinical relevance. APO-1 was found on some lymphoid tumor cells freshly isolated from patients. Thus, anti-APO-1 might be useful as a diagnostic tool to define subsets of normal and malignant lymphocytes. In addition, induction of apoptosis may have implications for anti-tumor therapy. Antibodies have frequently been used as heteroconjugates with toxins or drugs to destroy tumor cells (17). Our data, however, show that MAb alone can be lethal to target cells. Anti-APO-1 and related MAbs might, therefore, be considered for ex vivo or in vivo therapy, under conditions where reactivity with vital normal cells can be excluded or tolerated. Finally, the molecular investigation of cell death induced by anti-APO-1 might lead to a general understanding of apoptosis. In this case, the use of modified or normal physiological ligands to the cell surface antigen initiating apoptosis or of chemicals interfering with the apoptotic signal might be envisaged.

#### REFERENCES AND NOTES

1. E. Duvall and A. H. Wyllie, *Immunol. Today* 7, 115 (1986).
2. A. H. Wyllie, J. F. R. Kerr, A. R. Currie, *Int. Rev. Cytol.* 68, 251 (1980).
3. BALB/c mice were immunized once per week over a 4-week period by intraperitoneal injection of  $1 \times 10^7$  SKW6.4 cells. Four days after the last injection, spleen cells from immunized animals were fused with the P3.X63.Ag8.653 myeloma [G. Köhler and C. Milstein, *Nature* 256, 495 (1975)]. Twelve days after fusion culture supernatants from wells positive for growth were tested for their ability to inhibit growth of SKW6.4 cells. Hybridomas that produced blocking MAbs were cloned three times by limiting dilution at a concentration of 0.5 cells per well. MAbs were purified from serum-free culture supernatant by means of a protein A-Diasorb column (Diagen, Düsseldorf, FRG). Bound MAbs were eluted with 0.1M NaCl and 0.1M glycine, pH 2.8, dialyzed against phosphate-buffered saline and sterilized. The isotype of the MAbs was determined by enzyme-linked immunosorbent assay [S. Kiesel, *et al.*, *Leuk. Res.* 11, 1119, 1987] with isotype-specific goat anti-mouse Ig that had been conjugated with horseradish peroxidase (Dunn, Asbach, FRG).
4. Affinity and number of anti-APO-1 binding sites per cell were determined by Scatchard analysis as described [I. von Hoegen, W. Falk, G. Kojouharoff, P. H. Kramer, *Eur. J. Immunol.* 19, 329 (1989)]. Briefly, MAbs were iodinated by the IODO-Gen method [P. J. Fraken and J. C. Speck, *Biochem. Biophys. Res. Commun.* 80, 849 (1980)]. Aliquots of  $5 \times 10^5$  cells were resuspended in 200  $\mu$ l of culture medium containing 0.1%  $\text{NaN}_3$  and different concentrations of  $^{125}\text{I}$ -labeled MAbs. After incubation at 4°C for 4 hours, two 95- $\mu$ l portions were removed and centrifuged as described above by von Hoegen *et al.*
5. A. H. Wyllie, *Nature* 284, 555 (1980).
6. Monoclonal anti-CD19 (HD37) and anti-CD22 (HD39) were kindly provided by B. Dörken (Poliklinik of the University, Heidelberg, FRG) and monoclonal anti-CD20 by G. Moldenhauer (IV Leukocyte typing workshop and conference, Vienna, Austria, 1989), respectively. The 18 nonbinding and 9 binding MAbs of the IgG 3 isotype (tested by immunofluorescence on SKW6.4 cells) and the MAbs directed against MHC class II, IgM, and SKW6.4 Ig idiotypes were raised in our own laboratory.
7. The kinetics of membrane blebbing induced by anti-APO-1 (within 30 min; Fig. 2a) was not influenced by the presence of 10 mM EDTA or EGTA. In addition, endonuclease-mediated DNA fragmentation induced by anti-APO-1 was not inhibited by the  $\text{Ca}^{2+}$  channel blockers Fluramin (50  $\mu$ M) or Nifedipin (50  $\mu$ M).
8. When  $^{51}\text{Cr}$ -labeled SKW6.4 cells were incubated with anti-APO-1 (1  $\mu$ g/ml) for 2, 4, 8, and 24 hours, the specific  $^{51}\text{Cr}$  release [R. C. Duke, R. Chervenak, J. J. Cohen, *Proc. Natl. Acad. Sci. U.S.A.* 80, 6361 (1983)] was found to be 2.9%, 7.6%, 21.3%, and 32.5%, respectively. Trypan blue uptake was measured at the same time points: 2.5%, 4.7%, 10.6%, and 73.6%, respectively, of the cells were trypan blue-positive. In contrast, 2 hours after the addition of MAbs, plus complement the specific  $^{51}\text{Cr}$  release was 108.7% and 92.7% of the cells stained with trypan blue.
9. Two hours after addition of MAbs (1  $\mu$ g/ml) the genomic DNA of each tumor line was isolated and analyzed on agarose gels as described (Fig. 2). Inhibition of [ $^3\text{H}$ ]thymidine uptake by anti-APO-1 was paralleled by fragmentation of the genomic DNA. This was not observed after treatment with control MAb (I3B1).
10. Activated B cells ( $10^6$  per milliliter) were incubated in the presence of MAb FII23 or anti-APO-1 at 1  $\mu$ g/ml. After 3 days the culture supernatants were collected and the IgM concentration measured with a human IgM-specific ELISA containing HRP-conjugated goat anti-human IgM (Medac, Hamburg, FRG). IgM secretion after treatment with FII23 or anti-APO-1 was 2100 and 550 ng/ml, respectively.
11. OCI-LY1 was obtained from H. Messner, Ontario Cancer Institute, Toronto, Canada.
12. D. Pressman *et al.*, *Cancer Res.* 17, 845 (1957).
13. S. L. Brown *et al.*, *Blood* 73, 651 (1989).
14. C. A. Smith *et al.*, *Nature* 337, 181 (1989).
15. D. S. Schmid, J. P. Tite, N. H. Ruddle, *Proc. Natl. Acad. Sci. U.S.A.* 83, 1881 (1986); G. B. Deatry, M. S. Naylor, W. Fiers, F. R. Balkwill, *Eur. J. Immunol.* 17, 689 (1987); M. M. Don *et al.*, *Aust. J. Exp. Biol. Med. Sci.* 55, 407 (1977); C. J. Sanderson, *Biol. Rev.* 56, 153 (1981); J. H. Russell and C. B. Dobos, *J. Immunol.* 125, 1256 (1980); D. M. Howell and E. J. Martz, *Immunology* 140, 689 (1988); J. C. Hiserodt, L. J. Britvan, S. R. Tag Targan, *J. Immunol.* 129, 1782 (1982); J. D.-E. Young and C.-C. Liu, *Immunol. Today* 9, 140 (1988).
16. F. Giorgi and P. J. Deri, *Embryol. Exp. Morphol.* 35, 521 (1976).
17. E. S. Vitetta *et al.*, *Science* 219, 644 (1983).
18. V. K. Laemmli, *Nature* 277, 680 (1970).
19. The CCRF-CEM.S2 subclone was obtained by cloning cells under limiting dilution conditions from the CCRF-CEM T cell line at one cell per well in 96-well microtiter plates. CCRF-CEM.S2 was selected because of its high sensitivity to programmed cell death induced by anti-APO-1 (500 ng/ml) as measured by microscopic inspection in a 4-hour culture.
20. M. Madsen *et al.*, *J. Immunol. Methods* 33, 323 (1980); M. A. Pellegrino *et al.*, *Clin. Immunol. Immunopathol.* 3, 324 (1975).
21. T. R. Jerrells, J. H. Dean, G. L. Richardson, D. B. Herberman, *J. Immunol. Methods* 32, 11 (1980).
22. We thank K. Hexel, J. Köllner, R. Kühn, C. Mandl, and W. Müller for excellent technical assistance; H. Sauter for excellent secretarial assistance; G. Hämmerling and G. Moldenhauer for their criticism; B.

Dörken and G. Moldenhauer for providing MAbs, and Dr. H. Messner for providing tumor cells. We also thank D. Scheppelmann and H.-P. Meinzer for the computerized image analysis of normal and apoptotic cells. Supported by grants from the Bundesministerium für Forschung und Technolo-

gie, Bonn, the Ministerium für Wissenschaft und Kunst, Stuttgart, and the Tumor Center Heidelberg/Mannheim, FRG. A.M.J.P. was supported by the Boehringer Ingelheim Fonds, Stuttgart, FRG.

3 February 1989; accepted 19 May 1989

## The Reservoir for HIV-1 in Human Peripheral Blood Is a T Cell That Maintains Expression of CD4

STEVEN M. SCHNITTMAN,\* MILTIADES C. PSALLIDOPOULOS, H. CLIFFORD LANE, LOUIS THOMPSON, MICHAEL BASELER, FERDINAND MASSARI, CECIL H. FOX, NORMAN P. SALZMAN, ANTHONY S. FAUCI

Human immunodeficiency virus type 1 (HIV-1) selectively infects cells expressing the CD4 molecule, resulting in substantial quantitative and qualitative defects in CD4<sup>+</sup> T lymphocyte function in patients with acquired immunodeficiency syndrome (AIDS). However, only a very small number of cells in the peripheral blood of HIV-1-infected individuals are expressing virus at any given time. Previous studies have demonstrated that *in vitro* infection of CD4<sup>+</sup> T cells with HIV-1 results in downregulation of CD4 expression such that CD4 protein is no longer detectable on the surface of the infected cells. In the present study, highly purified subpopulations of peripheral blood mononuclear cells (PBMCs) from AIDS patients were obtained and purified by fluorescence-automated cell sorting. They were examined with the methodologies of virus isolation by limiting dilution analysis, *in situ* hybridization, immunofluorescence, and gene amplification. Within PBMCs, HIV-1 was expressed *in vivo* predominantly in the T cell subpopulation which, in contrast to the *in vitro* observations, continued to express CD4. The precursor frequency of these HIV-1-expressing cells was about 1/1000 CD4<sup>+</sup> T cells. The CD4<sup>+</sup> T cell population contained HIV-1 DNA in all HIV-1-infected individuals studied and the frequency in AIDS patients was at least 1/100 cells. This high level of infection may be the primary cause for the progressive decline in number and function of CD4<sup>+</sup> T cells in patients with AIDS.

**T**HE HUMAN IMMUNODEFICIENCY virus type 1 (HIV-1), the etiologic agent of the acquired immunodeficiency syndrome (AIDS), selectively infects cells expressing the CD4 molecule, including T lymphocytes and cells of the monocyte/macrophage lineage (1). *In vitro* infection of cells with HIV-1 results in a decreased expression of the CD4 molecule on the surface of the infected cells (2).

Patients with AIDS have severe depression of the normal cell-mediated immune mechanisms that is partially attributed to the considerable depletion of CD4 lymphocytes (3). Despite this, examination of cells from lymph nodes and peripheral blood from patients with AIDS and AIDS-related complex (ARC) has revealed a very low frequency of viral RNA synthesis, generally occurring in 1/100,000 to 1/10,000 of total mononuclear cells (4). However, it is possible that a larger proportion of cells may be latently infected (containing proviral DNA but not expressing viral mRNA or protein). Until the development of gene amplification [polymerase chain reaction (PCR)] methodology (5, 6), HIV-1-infected cells not expressing virus were not readily detectable by

available techniques.

In the present study, blood was obtained from HIV-1 culture-positive patients with AIDS either directly in heparinized syringes or via apheresis and subjected to Ficoll-Hypaque separation (7). First, peripheral blood mononuclear cells (PBMCs) from patients were stained with fluorescein isothiocyanate (FITC)-conjugated antibody to CD3 and sorted by a fluorescence-activated cell sorter (FACS) into CD3<sup>+</sup> and CD3<sup>-</sup> populations. Sorted cells were cocultivated with an excess of normal phytohemagglutinin (PHA)-stimulated blast cells and we determined the time to peak viral expression, a highly consistent and reproducible parameter of viral expression. A predominance of HIV-1 expression in the >98% enriched CD3<sup>+</sup> population, as determined by the time to peak syncytia formation (Fig. 1A) and reverse transcriptase (RT) activity (Fig. 1B), was seen. Similar results were obtained in seven additional AIDS patients. Delayed expression of HIV-1 in cells that were initially 99% CD3<sup>-</sup> cells (Fig. 1B) was due to outgrowth of the few contaminating CD3<sup>+</sup> cells. Phenotypic analysis of noncocultivated enriched CD3<sup>-</sup> cells grown under

the same conditions revealed that 35 to 65% of the cells were CD3<sup>+</sup> by day 10 in culture.

In the second series of experiments, PBMCs from AIDS patients were double-stained with FITC-conjugated anti-CD3 and anti-CD4 and sorted by FACS into CD3<sup>+</sup>/CD4<sup>+</sup> and CD3<sup>+</sup>/CD4<sup>-</sup> populations. These sorted cells were cocultivated with an excess of normal PHA-stimulated blast cells and showed a predominance of HIV-1 expression in the highly enriched (98 to 99%) CD4<sup>+</sup> T cell population as determined by the time to peak syncytia formation (Fig. 1C) and RT activity (Fig. 1D). Similar results were obtained in seven additional AIDS patients. The phenotypic analysis of freshly sorted CD3<sup>+</sup>/CD4<sup>+</sup> cells revealed a greater than 98 to 99% CD4<sup>+</sup> purity in most experiments when stained with the monoclonal antibody to Leu 3a. Again, the delayed expression of HIV-1 in cells that were initially 99% CD4<sup>-</sup> (Fig. 1D) was most likely due to outgrowth of a few contaminating CD4<sup>+</sup> T cells. Phenotypic analysis of non-cocultured enriched CD4<sup>-</sup> T cells grown under the same conditions revealed that 30 to 55% of the cells were CD4<sup>+</sup> by day 10 in culture.

*In situ* hybridization for HIV-1 viral RNA was then performed at time zero on the highly enriched CD3<sup>+</sup>/CD4<sup>+</sup>- and CD3<sup>+</sup>/CD4<sup>-</sup>-sorted PBMCs. There was a predominance of viral expression in the CD4<sup>+</sup> T cell population at a frequency of about 1/1000 cells in four AIDS patients ( $\bar{X} \pm \text{SEM}$  per 1000 cells was  $0.95 \pm 0.21$ ) (Fig. 2A). This is in comparison to a level of viral expression in the CD4<sup>-</sup> T cell population of <1/100,000 cells (Fig. 2B), which is equivalent to background signal in controls. The frequency of *in situ*-positive CD4<sup>+</sup> T cells remained unchanged in three of the patients reexamined at 6 to 12 months after the initial studies.

Indirect immunofluorescence studies for HIV-1 viral antigens was also performed at time zero on highly enriched CD3<sup>+</sup>/CD4<sup>+</sup>- and CD3<sup>+</sup>/CD4<sup>-</sup>-sorted PBMCs. These demonstrate a predominance of viral expression in the CD4<sup>+</sup> T cell population at a frequency of about 1/1000 cells in four AIDS patients ( $\bar{X} \pm \text{SEM}$  per 1000 cells was  $1.10 \pm 0.35$ ) (Fig. 2C). This is in comparison to a level of viral expression in the CD4<sup>-</sup> T cell population of <1/10,000 cells

S. M. Schnittman, H. C. Lane, F. Massari, C. H. Fox, A. S. Fauci, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.

M. C. Psallidopoulos, L. Thompson, N. P. Salzman, Division of Molecular Virology and Immunology, Georgetown University School of Medicine, Washington, DC 20007.

M. Baseler, Program Resources, Incorporated, Frederick, MD 21701.

\*To whom correspondence should be addressed.